2 September 2022 - Novavax today announced that Swissmedic has expanded its temporary authorisation of Nuvaxovid COVID-19 vaccine in Switzerland for active immunisation to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 in adolescents aged 12 through 17 and as a heterologous and homologous booster dose for adults aged 18 and older.
The authorisation for adolescents aged 12 through 17 is based on data from the on-going paediatric expansion of the Phase 3 PREVENT-19 trial of 2,247 adolescents aged 12 through 17 years across 73 sites in the US to evaluate the safety, effectiveness (immunogenicity), and efficacy of Nuvaxovid.